Ask AI
ProCE Banner Activity

Phase I Trial of the KRAS G12D Inhibitor HRS-4642 in Previously Treated Advanced KRAS G12D–Mutant NSCLC and PDAC

Slideset

A phase I study of the KRAS G12D inhibitor HRS-4642 demonstrated a manageable safety profile and preliminary activity in patients with previously treated advanced KRAS G12D–mutant advanced NSCLC and PDAC. 

Released: October 29, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly